Growing Risks From Malicious Drones
The risk of long-distance attacks by malicious drones, long thought to be only theoretical, now seems to be very real.
The risk of long-distance attacks by malicious drones, long thought to be only theoretical, now seems to be very real.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Every customer now expects organizations to have a single, unified view of their relationship that includes all their interactions.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Gautam Jit Kanwar is president at BelWo, a global managed services provider specializing in customer communications management (CCM).
As risk morphs, leaders must build a sound risk culture, and underwriters must consider the risk culture of accounts they write.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Donna Galer is a consultant, author and lecturer.
She has written three books on ERM: Enterprise Risk Management – Straight To The Point, Enterprise Risk Management – Straight To The Value and Enterprise Risk Management – Straight Talk For Nonprofits, with co-author Al Decker. She is an active contributor to the Insurance Thought Leadership website and other industry publications. In addition, she has given presentations at RIMS, CPCU, PCI (now APCIA) and university events.
Currently, she is an independent consultant on ERM, ESG and strategic planning. She was recently a senior adviser at Hanover Stone Solutions. She served as the chairwoman of the Spencer Educational Foundation from 2006-2010. From 1989 to 2006, she was with Zurich Insurance Group, where she held many positions both in the U.S. and in Switzerland, including: EVP corporate development, global head of investor relations, EVP compliance and governance and regional manager for North America. Her last position at Zurich was executive vice president and chief administrative officer for Zurich’s world-wide general insurance business ($36 Billion GWP), with responsibility for strategic planning and other areas. She began her insurance career at Crum & Forster Insurance.
She has served on numerous industry and academic boards. Among these are: NC State’s Poole School of Business’ Enterprise Risk Management’s Advisory Board, Illinois State University’s Katie School of Insurance, Spencer Educational Foundation. She won “The Editor’s Choice Award” from the Society of Financial Examiners in 2017 for her co-written articles on KRIs/KPIs and related subjects. She was named among the “Top 100 Insurance Women” by Business Insurance in 2000.
Let's spend a minute understanding just how dysfunctional the system for pharmaceuticals is.
As we wait to see what exactly happens because of the executive order that the Trump administration promises to use to cut drug prices in the U.S. (while keeping our fingers firmly crossed), let's spend a minute understanding just how dysfunctional the system for pharmaceuticals is.
If you want full-on fury, read this article, which likens Big Pharma to organized crime. But, even if you don't want to go nearly that far, it's hard to argue that the system isn't broken.
Pramod John, probably the smartest person I know on the subject of drug prices, contends that the U.S. Food and Drug Administration focuses on safety but not enough on the effectiveness of pharmaceuticals.
And, once approval is secured, Big Pharma is free to do pretty much whatever it wants in terms of pricing. By law, Medicare has to cover every drug approved by the FDA at whatever price the drug companies want to charge. As this editorial in the New York Times notes, Medicaid likewise has to cover every approved drug; "the program receives an across-the-board discount from drug makers, but, as critics note, that discount has not kept pace with the changing drug market." Private insurers and the Department of Veterans Affairs can negotiate, but separately, diminishing their power to bargain with Big Pharma.
By contrast, Britain and Germany, among others, tie price to value: The government will only pay for new drugs if they represent a clear improvement over old drugs.
The situation in the United States is made worse by a trend toward speedy approval for drugs. A system set up to fast track drugs that could help desperate patients has been turned on its head: Now, as the Wall Street Journal reported last week, at least 60% of drugs approved in the past five years have been handled on an expedited basis.
Increasingly, drugs don't have to demonstrate actual improvement in patients; the drugs just have to show progress on some interim measure. So, a drug company doesn't have to show that a cancer drug increases patients' lifespans or improves their quality of life, merely that, say, the drug shrinks tumors.
Improvement on interim measures, no matter how logical, often doesn't translate into benefits for patients—yet, if no safety problems are found, a drug finds its way into the market, often at a startling price.
In short, oversight of the pharmaceutical industry has become ineffective and medicine has become wildly expensive.
Let's hope we—the patients, insurance clients and taxpayers—get some relief. But it won't be easy, even if the coming executive order is everything that can be hoped. It's taken us decades to create the pharmaceutical mess; it'll take time for us to get out of it.
Cheers,
Paul Carroll
Editor-in-Chief
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Paul Carroll is the editor-in-chief of Insurance Thought Leadership.
He is also co-author of A Brief History of a Perfect Future: Inventing the Future We Can Proudly Leave Our Kids by 2050 and Billion Dollar Lessons: What You Can Learn From the Most Inexcusable Business Failures of the Last 25 Years and the author of a best-seller on IBM, published in 1993.
Carroll spent 17 years at the Wall Street Journal as an editor and reporter; he was nominated twice for the Pulitzer Prize. He later was a finalist for a National Magazine Award.
While some see scenario planning as academic, it typically yields surprising insights that inform short-term and mid-term strategies.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Mark Breading is a partner at Strategy Meets Action, a Resource Pro company that helps insurers develop and validate their IT strategies and plans, better understand how their investments measure up in today's highly competitive environment and gain clarity on solution options and vendor selection.
Insurers must develop digital tools and surround them with a human element, such as real-time access to financial advisers.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Bernhard Klein Wassink serves as the EY global customer and growth leader for insurance. He assists clients in developing growth strategies, increasing distribution effectiveness, improving customer experience and embedding digital strategies for growth.
Recent studies contend that consumers don't trust insurance agents, but the research misses a crucial point.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
William C. Wilson, Jr., CPCU, ARM, AIM, AAM is the founder of Insurance Commentary.com. He retired in December 2016 from the Independent Insurance Agents & Brokers of America, where he served as associate vice president of education and research.
As much as the focus has been on an engaging experience, work has to be done on the back end, too, to address age-old problems.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Vinod Kachroo is the visionary responsible for leading innovation at SE2 to develop a technology platform that’s future-proofed.
It's human nature to be attracted to people, yet technology drives so many dealings with firms. How do we bridge this dichotomy?
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
About 60 million people speak a language other than English at home in the U.S.; 37 million speak Spanish, and a million speak Tagalog.
Get Involved
Our authors are what set Insurance Thought Leadership apart.
|
Partner with us
We’d love to talk to you about how we can improve your marketing ROI.
|
Ofer Tirosh is the CEO of Tomedes, a translation company that helps businesses all over the world boost their customer retention through quality marketing translation services.